One of the pioneers in biotechnology, Biogen today has the leading portfolio of medicines to treat multiple sclerosis (MS), has the first and only approved treatment for spinal muscular atrophy (SMA) and is at the forefront of research into new medicines for neurological and neurodegenerative conditions. Led by world-class research and development, Biogen uses novel science and leading-edge technologies to create, commercialize, and manufacture transformative therapies for patients with few or no treatment options.
For more than two decades, Biogen has transformed the understanding and treatment of MS. Today, our research is focused on developing new MS treatments with the goal of repairing damage caused by the disease – and ultimately working to find a cure.
We are further applying our expertise to solve some of the most challenging and complex diseases in neurology, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The pace of discovery and innovation in neuroscience is accelerating rapidly, bringing the promise of incredible advances to patients. As we help lead this transformative period in neuroscience, Biogen is driving a deeper understanding of disease biology and working to develop potentially life-changing treatments for the people suffering from these conditions.
As we uncover new insights into human biology, Biogen is using cutting-edge technologies to pursue treatments for rare and genetic disorders and explore entirely new ways to treat disease through the advancement of RNA medicines and gene therapy.